<i>In-vitro, in-vivo</i> and computational experiments for the antidiabetic potential of bioactive compound from <i>Notholirion thomsonianum</i>

Diabetes mellitus is a prevalent condition that significantly impacts the lifestyles of a large portion of the global population. This study aims to explore the efficacy of isolated compound from <i>Notholirion thomsonianum</i> in the treatment of diabetes mellitus. The compound, 2-veratryl-3,7-dihydroxy-4-one (<b>Comp-1</b>) analogue, an isolated bioactive from <i>N. thomsonianum</i> is now evaluated for its α-glucosidase and α-amylase activities. Initially, the isolated flavone (<b>Comp-1</b>) showed IC₅₀ values of 4.20 μg/mL and 3.83 μg/ml against α-glucosidase and α-amylase, respectively. The IC₅₀ values of the standard acarbose against α-glucosidase and α-amylase were 4.12 and 3.03 μg/ml, respectively. The binding associations for α-glucosidase, α-amylasewere promising. In-vivo analysis the <b>Comp-1</b> displayed blood glucose level up to 117 at 28^th day while the standard drug glibenclamide displayed 104. The body weight changes were observed upto 250 and 247 as that in the standard and tested <b>Comp-1</b>. Based on the latest findings, it is evident that the isolated chemical <b>Comp-1</b> had activity against alpha amylase and glucosidase. The <b>Comp-1</b> had the greatest potency in all in-vitro testing. The molecular docking analyses supported our in-vitro findings. The study concludes that <i>N. thomsonianum</i> has a significant amount of bioactive chemicals with antidiabetic properties. These findings suggest the potential for conducting in-vivo tests in the future.